CF PharmTech, Inc. (2652) has announced that, following the quarterly review of the Hang Seng Family of Indexes for the period ended December 31, 2025, it will be included as a constituent stock of the Hang Seng Composite Index. The change takes effect on March 9, 2026.

The announcement highlights that the Hang Seng Composite Index covers about 95% of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited. The management of CF PharmTech, Inc. states that this inclusion reflects the capital market’s recognition of its position in the respiratory disease treatment market and the capabilities across its comprehensive inhalation drug delivery platform.

CF PharmTech, Inc. specializes in developing complex inhalation formulations with high barriers to entry, supported by globally integrated end-to-end capabilities in device engineering, precision drug delivery, global regulatory filing, and commercialization. The company’s focus areas include respiratory and nasal diseases, with strategic initiatives expanding into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and central nervous system disorders.

The company has established a multi-dimensional commercialization network in China and is steadily advancing in international markets with globally compliant manufacturing systems. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.